TY - JOUR T1 - Current Status of Therapeutic Drug Monitoring of 5-Fluorouracil Prodrugs JF - Anticancer Research JO - Anticancer Res SP - 4655 LP - 4661 DO - 10.21873/anticanres.14464 VL - 40 IS - 8 AU - YASUHIRO HASHIMOTO AU - YOICHIRO YOSHIDA AU - TEPPEI YAMADA AU - NAOYA AISU AU - GUMPEI YOSHIMATSU AU - FUMIHIRO YOSHIMURA AU - SUGURU HASEGAWA Y1 - 2020/08/01 UR - http://ar.iiarjournals.org/content/40/8/4655.abstract N2 - In recent years, therapeutic drug monitoring (TDM) of intravenous administration of 5-fluorouracil (5-FU) has resulted in reduced toxicity and improved efficacy. Prodrugs of 5-FU were developed to reduce toxicity, extend the duration of action, and increase tumour selectivity of 5-FU. These drugs are important in daily practice because of their ease of administration. Dose adjustment of 5-FU prodrugs by TDM is expected to reduce its toxicity and improve its efficacy. This review focuses on data from a recent study of personalized treatment using TDM of 5-FU and its prodrugs. ER -